Moreover, evidence suggests that TIGIT is highly expressed in mantle cell lymphoma cells in patients after relapse, and cotargeting TIGIT prevented CAR-T cell relapses, thereby promoting the long-term PFS of mantle cell lymphoma patients [215]. Here, TIGIT is linked to mantle cell lymphoma.